Skip to content
Sample Page
Author:
Entera Bio Ltd.
Posted Date:
June 22, 2026
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 – the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
Entera Bio Ltd.
June 22, 2026
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
Entera Bio Ltd.
June 16, 2026
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
Entera Bio Ltd.
June 15, 2026
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis – Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
Entera Bio Ltd.
May 28, 2026
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Entera Bio Ltd.
May 8, 2026
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
Entera Bio Ltd.
April 14, 2026
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
Entera Bio Ltd.
April 2, 2026
